Get started
Author

Nick A. Knudsen

Observed names: Nick Knudsen, Nickolas Knudsen
Observed institution: Ambrx (United States)
ORCID: 0009-0004-7026-0366
Observed ORCID: 0009-0004-7026-0366
OpenAlex ID: A5031305401
Optimized clinical performance of growth hormone with an expanded genetic code
2011 · Ho Cho, Tom Daniel, et al. · Proceedings of the National Academy of Sciences · 204
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2020 · Lillian Skidmore, Sukumar Sakamuri, et al. · Molecular Cancer Therapeutics · 170
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates
2016 · Jeffrey C. Kern, Mark Cancilla, et al. · Journal of the American Chemical Society · 148
In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
2014 · Dowdy Jackson, John Atkinson, et al. · PLoS ONE · 123
PDF
Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs
2016 · Jeffrey C. Kern, Deborah Dooney, et al. · Bioconjugate Chemistry · 98
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
2018 · Philip E. Brandish, Anthony Palmieri, et al. · Bioconjugate Chemistry · 60
Recruiting Cytotoxic T Cells to Folate‐Receptor‐Positive Cancer Cells
2013 · Sumith A. Kularatne, Vishal Deshmukh, et al. · Angewandte Chemie International Edition · 38
Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers
2015 · Robin C. Humphreys, Jessica Kirtely, et al. · Cancer Research · 31
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 23
PDF
Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development
2023 · Wayne Yu, Mysore Ramprasad, et al. · PLoS ONE · 11
PDF
Recruiting Cytotoxic T Cells to Folate‐Receptor‐Positive Cancer Cells
2013 · Sumith A. Kularatne, Vishal Deshmukh, et al. · Angewandte Chemie · 9
Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection
2018 · Maribel Beaumont, Daniela Tomazela, et al. · AAPS Open · 6
PDF
Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle
2024 · Sarah E. Attreed, Christina Silva, et al. · Frontiers in Microbiology · 5
Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer
2023 · Lillian Skidmore, David Mills, et al. · Cancer Research · 5
Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate
2022 · Mingchao Kang, Sung-Ju Moon, et al. · Cancer Research · 4
Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types
2024 · David Mills, Ji Young Kim, et al. · Cancer Research · 1
Porcine interferon-alpha but not interferon-lambda inhibits replication of genotypically diverse PRRSV isolates in vitro
2026 · Samantha J. Hau, Steven G. Kellner, et al. · Frontiers in Veterinary Science
PDF
Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
Abstract 6318: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
2023 · Lillian Skidmore, Jingjing Zhu, et al. · Cancer Research
Supplementary Data Figure S1 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
PDF
Supplementary Data Figure S2 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Supplementary Data Figure S3 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Data from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
2023 · Lillian Skidmore, Sukumar Sakamuri, et al.
Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potential treatment of CD70 positive cancers
2016 · Lillian Skidmore, Kari Cox, et al. · Cancer Research
Works count: 27
Citation count: 936
H-index: 10
I10-index: 10
Year
Topic
Type